Caprock Group LLC Cuts Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Caprock Group LLC trimmed its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 6.5% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 1,296 shares of the biopharmaceutical company’s stock after selling 90 shares during the quarter. Caprock Group LLC’s holdings in Regeneron Pharmaceuticals were worth $1,362,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Rakuten Securities Inc. boosted its stake in Regeneron Pharmaceuticals by 380.0% during the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 19 shares during the last quarter. Stephens Consulting LLC purchased a new stake in Regeneron Pharmaceuticals during the 2nd quarter valued at $26,000. Sachetta LLC boosted its stake in Regeneron Pharmaceuticals by 71.4% during the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 10 shares during the last quarter. Crewe Advisors LLC bought a new position in shares of Regeneron Pharmaceuticals during the 1st quarter valued at $28,000. Finally, Lynx Investment Advisory bought a new stake in shares of Regeneron Pharmaceuticals in the second quarter worth $33,000. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts recently commented on the company. Piper Sandler cut their price objective on Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating for the company in a report on Friday, November 1st. Leerink Partnrs lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 24th. Barclays cut their price objective on Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating for the company in a report on Friday, November 1st. StockNews.com lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday, November 4th. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $1,015.00 price objective on shares of Regeneron Pharmaceuticals in a report on Wednesday, October 23rd. One analyst has rated the stock with a sell rating, four have assigned a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $1,099.55.

Insiders Place Their Bets

In other news, CFO Christopher R. Fenimore sold 5,680 shares of the company’s stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the transaction, the chief financial officer now owns 15,305 shares of the company’s stock, valued at approximately $18,447,575.65. This represents a 27.07 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 7.48% of the stock is currently owned by insiders.

Regeneron Pharmaceuticals Trading Down 0.2 %

Shares of NASDAQ REGN opened at $743.35 on Thursday. The business’s 50 day moving average is $961.76 and its two-hundred day moving average is $1,030.14. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. Regeneron Pharmaceuticals, Inc. has a 1-year low of $736.01 and a 1-year high of $1,211.20. The stock has a market capitalization of $81.69 billion, a P/E ratio of 18.40, a PEG ratio of 2.86 and a beta of 0.15.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.